Recent News

• 05.28.2025 - EyePoint Announces Participation at Upcoming Investor Conferences
• 05.28.2025 - EyePoint Announces Participation at Upcoming Investor Conferences
• 05.28.2025 - EyePoint Announces Participation at Upcoming Investor Conferences
• 05.27.2025 - EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU™ for Treatment of Wet Age-Related Macular Degeneration
• 05.27.2025 - EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU™ for Treatment of Wet Age-Related Macular Degeneration
• 05.20.2025 - RBC Capital Markets Global Healthcare Conference
• 05.20.2025 - RBC Capital Markets Global Healthcare Conference
• 05.16.2025 - EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• 05.16.2025 - EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• 05.13.2025 - EyePoint Announces Participation at Upcoming Investor Conferences

Recent Filings

• 05.27.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.27.2025 - 8-K Current report
• 05.27.2025 - EX-99.1 EX-99.1
• 05.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.15.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.09.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 05.08.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]